242 related articles for article (PubMed ID: 3001746)
1. Cholecystokinin-dopamine receptor interactions as studied with cholecystokinin receptor antagonists.
Murphy RB
Prog Clin Biol Res; 1985; 192():105-13. PubMed ID: 3001746
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides.
Fuxe K; Agnati LF; Benfenati F; Celani M; Zini I; Zoli M; Mutt V
J Neural Transm Suppl; 1983; 18():165-79. PubMed ID: 6192208
[TBL] [Abstract][Full Text] [Related]
4. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion.
Crawley JN
Synapse; 1989; 3(4):346-55. PubMed ID: 2740993
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin antagonists.
Maton PN; Jensen RT; Gardner JD
Horm Metab Res; 1986 Jan; 18(1):2-9. PubMed ID: 2419234
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity.
Makovec F; Bani M; Chisté R; Revel L; Rovati LC; Rovati LA
Arzneimittelforschung; 1986; 36(1):98-102. PubMed ID: 3006713
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
Zhou W; Povoski SP; Bell RH
J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro.
Voigt M; Wang RY; Westfall TC
J Pharmacol Exp Ther; 1986 Apr; 237(1):147-53. PubMed ID: 3958963
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
Chang RS; Lotti VJ; Chen TB; Kunkel KA
Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cholecystokinin receptor sites in guinea-pig cortical membranes using [125I]Bolton Hunter-cholecystokinin octapeptide.
Lin CW; Miller T
J Pharmacol Exp Ther; 1985 Mar; 232(3):775-80. PubMed ID: 2983069
[TBL] [Abstract][Full Text] [Related]
11. The effect of cholecystokinin-receptor antagonists on cholecystokinin-stimulated bile flow in dogs.
Westfall S; Andrus C; Schlarman D; Kaminski DL
Surgery; 1991 Mar; 109(3 Pt 1):294-300. PubMed ID: 2000561
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas.
Povoski SP; Zhou W; Longnecker DS; Bell RH
Oncol Res; 1994; 6(9):411-7. PubMed ID: 7703527
[TBL] [Abstract][Full Text] [Related]
13. New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues.
Niederau C; Niederau M; Williams JA; Grendell JH
Am J Physiol; 1986 Jun; 250(6 Pt 1):G856-60. PubMed ID: 2424321
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
[TBL] [Abstract][Full Text] [Related]
16. Cholecystokinin-8 regulation of NGF concentrations in adult mouse brain through a mechanism involving CCK(A) and CCK(B) receptors.
Tirassa P; Stenfors C; Lundeberg T; Aloe L
Br J Pharmacol; 1998 Mar; 123(6):1230-6. PubMed ID: 9559909
[TBL] [Abstract][Full Text] [Related]
17. Opposite effects of CCK(B) agonists in grooming behaviour in rats: further evidence for two CCK(B) subsites.
Ladurelle N; Sebret A; Garbay C; Roques BP; Daugé V
Br J Pharmacol; 1998 Jul; 124(6):1091-8. PubMed ID: 9720778
[TBL] [Abstract][Full Text] [Related]
18. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
[TBL] [Abstract][Full Text] [Related]
19. Structural features of various proglumide-related cholecystokinin receptor antagonists.
Jensen RT; Zhou ZC; Murphy RB; Jones SW; Setnikar I; Rovati LA; Gardner JD
Am J Physiol; 1986 Dec; 251(6 Pt 1):G839-46. PubMed ID: 2431626
[TBL] [Abstract][Full Text] [Related]
20. Regulation of dopamine D2 receptor affinity by cholecystokinin octapeptide in fibroblast cells cotransfected with human CCKB and D2L receptor cDNAs.
Dasgupta S; Li XM; Jansson A; Finnman UB; Matsui T; Rinken A; Arenas E; Agnati LF; Fuxe K
Brain Res Mol Brain Res; 1996 Mar; 36(2):292-9. PubMed ID: 8965650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
